Apogee Therapeutics Inc (APGE) Stock Price, Quote & News

Company Profile

Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other inflammatory and immunology indications. The company develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for the treatment of AD, which is in phase 2 clinical trials; and for the treatment of asthma and EoE which is in phase 1 clinical t...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 394 5230

Website: www.apogeetherapeutics.com

Address:

Building 17, Suite 102b 221 Crescent Street, Waltham, United States

TriggerRaider Aug. 23 at 5:46 AM

$APGE Apogee Therapeutics is a clinical stage immunology company with promising early data

0 · Reply

idk_idk Aug. 19 at 1:47 PM

$APGE Up or down from here?

0 · Reply

d_risk Aug. 12 at 1:03 AM

$APGE - Apogee Therapeutics Inc. Common Stock - 10Q - Updated Risk Factors APGE’s latest 10-Q risk factors streamline prior disclosures, add new warnings on limited operating history, funding needs, dual class stock, and forum selection, expand on FDA delays, compliance, and litigation risks, and remove several prior concerns including insider control, anti-takeover, and dividend policies. #Biotechnology #CorporateGovernance #FDADelays #FundingNeeds #RegulatoryRisk 🟢 Added 🟠 Removed https://d-risk.ai/APGE/10-Q/2025-08-11

0 · Reply